NCT00945217|Unknown
The Roles of SAH Gene Family in Athrogenic Dyslipidemia in Postmenopausal Women
MOSAH-S2
Genetic Probes of Atherogenic Dyslipidemia: The Roles of the SAH Gene Family (Study 2. Postmenopausal Women)
Loading search results
MOSAH-S2
Genetic Probes of Atherogenic Dyslipidemia: The Roles of the SAH Gene Family (Study 2. Postmenopausal Women)
Sponsor study identifier
observational
660
1 country
1
Study Start
October 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Atherogenic dyslipidemia is characterized by high levels of apolipoprotein B (apoB)-containing lipoproteins, including very-low-density lipoprotein (VLDL) and its remnants and small, dense LDL (sdLDL) particles, and reduced levels of high-density lipoprotein cholesterol (HDL-C). The National Cholesterol Education Program (NCEP) recommended using non-high-density lipoprotein cholesterol (non-HDL-C) to surrogate atherogenic lipoproteins in clinical practice. Recently, the investigators have done a pilot study to study the associations between SAH gene variants and atherogenic dyslipidemia (surrogated by non-HDL-C) in postmenopausal women. The investigators found that homozygosity for SAH haplotype 3 was associated with increased adiposity, insulin resistance, and elevated levels of non-HDL-C in the postmenopausal women. Based on the findings of the pilot study, the investigators plan to expand the cohort of postmenopausal women to about 800 women, that is, recruited 660 new subjects in two years. The associations between non-HDL-C and the SAH gene family will be done. Fasting blood sampling for buffy coats and lipids is the core test of Study 2. A 75-g oral glucose tolerance test (OGTT) will be available as an optional test for a better phenotyping of insulin resistance for the participants. Detailed lipid profiling including measurements of VLDL cholesterol, VLDL-TG, remnant lipoprotein, LDL particle size, apoA1, apoB, and apoCIII will be done in the second year of the study if significant associations between gene variants of the SAH gene family and non-HDL-C are detected.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 17, 2009
Actual (reported)July 24, 2009
Actual (reported)October 2009
Date type not reportedThis date has not been verified as actual or estimated.
March 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
the differences in haplotype frequencies of the SAH gene between two groups of subjects with different levels of non-HDL-C.
2 years
the differences in haplotype frequencies of other members of the SAH gene family between two groups of subjects with different levels of non-HDL-C.
2 years
women with natural menopause
Volunteers with natural menopause from a research clinic
Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital
Taipei, 112, Taiwan
Samples With DNA - samples retained, with potential for extraction of DNA from buffy coats
Chii-Min Hwu, MD
Taipei Veterans General Hospital, Taiwan
First Submitted
April 17, 2009
First Posted
July 24, 2009
Study Start
October 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2012
A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)
ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2012
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 6, 2011
Record last verified: 2011-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: